To further confirm the importance of AKT1 activation in FDFT1 regulating HCC, we used the AKT1 inhibitor (MK‐2206) and agonists (SC79) in FDFT1 overexpression and knockdown cells, respectively.[15] The EdU labeling, migration, and invasion assays suggested that the AKT1 agonist restored the inhibitory effects of FDFT1 knockdown on cell proliferation and metastasis (Figure S5D,F, Supporting Information), while the AKT1 inhibitor eliminated the effects of FDFT1 overexpression on promoting cell proliferation and metastasis (Figure S5E,G, Supporting Information). The gene discussed is FDFT1; the disease is hepatocellular carcinoma.